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Artemisinin and its derivatives are widely used in the world as the first-line antimalarial drug. Recently, growing evidences
reveal that artemisinin and its derivatives also possess potent anti-inflammatory and immunoregulatory properties. Meanwhile,
researchers around the world are still exploring the unknown bioactivities of artemisinin derivatives. In this review, we provide a
comprehensive discussion on recent advances of artemisinin derivatives affecting inflammation and autoimmunity, the underlying
molecular mechanisms, and also drug development of artemisinins beyond antimalarial functions.
1. Introduction
Artemisinin was isolated from Artemisia annua L. in 1972 by
Chinese researchers. At the end of 1975, its unique chem-
ical structure was elucidated, as a sesquiterpene lactone
bearing a peroxy group, quite different from that of all
known antimalarial drugs (reviewed in [1]). Artemisinin and
its derivatives are currently considered the most effective
drug in treating cerebral malaria and chloroquine resis-
tant falciparum malaria [2, 3]. It is also recognized as the
“best hope for the treatment of malaria” by the World
Health Organization because of its effectiveness, nonresistant
characteristics, and minimal side effects [2, 3]. The active
metabolite of artemisinin is dihydroartemisinin (DHA).
Currently, artemisinin derivatives used in clinical treatment
include DHA, artemether, artesunate, and arteether. In addi-
tion to their excellent antimalarial effects, the clinical and
experimental studies also suggested that artemisinin and
its derivatives possess potent immune-suppressive abilities
to treat autoimmune and allergic diseases. Recently, sci-
entists from Shanghai Institute of Materia Medica (SIMM,
CAS) designed a series of novel artemisinin derivatives
with lower toxicity, higher bioavailability, and potent
immunosuppressive activity. In this paper, we will review
the progress of the anti-inflammation and immunoregu-
latory studies of artemisinin family compounds includ-
ing both commercial available and newly synthesized
ones including 3-(12-𝛽-artemisininoxy) phenoxyl succinic
acid (SM735) [4], 1-(12-𝛽-dihydroartemisinoxy)-2-hydroxy-
3-tert-butylaminopropane maleate (SM905) [5–7], ethyl 2-
[4-(12-𝛽-artemisininoxy)] phenoxylpropionate (SM933) [8],
and 2󸀠-aminoarteether (𝛽)maleate (SM934) [9–12] (chemical
structures were shown in Figure 1). Of note, the SM934 is
recently approved by the China Food and Drug Adminis-
tration for clinical trial as novel therapeutic agent to treat
systemic lupus erythematosus (SLE).
2. Antimalarial Mechanism of Artemisinin
Artemisinin is a sesquiterpene lactone containing peroxide
bridge. Studies have shown that peroxide bridge plays an
essential role in antimalarial pathways for artemisinin. The
damage or absence of such peroxide bridge will reduce or
even diminish the antimalarial effect. In contrast, leaving
peroxide bridge untouched, antimalarial effect of artemisinin
remains, no matter how the sesquiterpene was chemically
modified [13, 14].
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Figure 1: Chemical structure of artemisinin and its derivatives.
To date, it is broadly accepted that artemisinin exerts
antimalarial effects through the following molecular mech-
anisms: Heme or free iron will break the peroxide bridge,
which results in the degradation of the molecular structure
of artemisinin to form the nucleophilic radical metabolites
with the center of C
4
. Consequently, the free radicals, acting
as an alkylating agent, will attack macromolecular bearing
electrophilic groups or centers, which eventually leads to
parasitic death [14, 15]. Actually, the red blood cells have
high level of oxidative stress once they are infected with
Plasmodium. Meanwhile, the intracellular free radicals and
lipid peroxidation level will dramatically increase due to
oxidative stress. As a result, parasite-infected red blood cells
will increase their susceptibility to artemisinin. Accordingly,
in vivo, artemisinin is effective in killing parasite-infected red
blood cells at nM levels; in sharp contrast, artemisinin only
shows marginal effects on resting red blood cells, even with
the concentration as high as mM levels [16, 17].
3. Anti-Inflammation and Immunoregulatory
Effect of Artemisinin
3.1. In Vitro Immunosuppressive Activity. T cells play pivotal
role in acquired immune reaction, which includes three fun-
damental steps [18, 19]. First, TCR cross-linking drives T cells
from G0 to G1 transition and subsequent secretion of T cell
growth factor IL-2 and expression of high-affinity receptor
IL-2R𝛼 chain (CD25). Second, through autocrine/paracrine
proliferative loop, IL-2 induces clone expansion and main-
tains survival of activated T cells.Third, after successful clear-
ance of the pathogen, the stimulus for cytokines production
is lost and activated T cells thus will undergo apoptosis.
However, in autoimmune diseases, due to the persistence
of autoantigen, autoreactive T cells will be activated and
survive better. Autoreactive T cell proliferation is involved
in the pathogenesis of various autoimmune diseases, such
as rheumatoid arthritis (RA) and multiple sclerosis (MS)
[20, 21]. Artemether is a potent antimalarial drug [1]. In 2007,
Wang et al. found artemether significantly suppressed the
proliferation and IL-2 and interferon-𝛾 (IFN-𝛾) production
of T cells triggered by TCR engagement [22]. Artemether
significantly inhibited TCR engagement-triggered MAPKs
signaling pathway including phosphorylation of ERK1/2, Jnk,
and P38. Authors further dissected that artemether majorly
affected the function of T cells, rather than the antigen-
presenting cells (APCs) to exert the immunosuppressive
effects.
In recent years, by inserting new groups to the parent
structure of artemisinin, Li from SIMM synthesized a series
of artemisinin derivatives with higher water solubility and
lower toxicity [23–25]. The new compounds were screened
for in vitro immunosuppressive activity, majorly focused on
suppressing T cell activation. SM735, one of artemisinin
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derivatives developed by Li group, substantially inhibited
the proliferation and IFN-𝛾 production of mitogen Con A-
stimulated splenocytes [4]. It also significantly suppressed
the IL-12, IFN-𝛾, and IL-6 productions from LPS-stimulated
splenocytes. SM934 and SM905 were recently synthesized
derivatives by Li group in SIMM [23, 25]. Similar to SM735,
the studies in Zuo group in SIMM found SM905 possessed
potent immunoregulatory properties [5–7].
However, SM934 is quite distinct [11]. Similar to SM905
and artemether, in vitro, SM934 significantly inhibited the
proliferation and IFN-𝛾 production of splenocytes or purified
CD4+ T cells induced by mixed lymphocyte reaction (MLR)
or TCR cross-linking. In sharp contrast to all of SM905,
SM735, and artemether, SM934 exerted no influence on IL-
2 production and CD25 upregulation of T cells but could
remarkably suppress IL-2-mediated proliferation and sur-
vival of activated T cells, which might be the consequence of
blocking IL-2-induced phosphorylation of Akt. In addition,
through combined staining of CD69 and annexin V, SM934
was found to preferentially promote activated T cells into
early apoptosis, leaving resting T cells untouched.
Moreover, there are also studies suggesting that artemi-
sinin derivatives will bind to calmodulin to inhibit phospho-
diesterase activity, which causes the increase of intracellular
cAMP level, and thus to exert the immunosuppressive activity
[26, 27].
3.2. Artemisinin Derivatives Treat Rheumatoid Arthritis.
Collagen-induced arthritis (CIA) is a classic murine model
of human rheumatoid arthritis. In CIA model, SM905 could
dramatically prevent or treat arthritis, which was manifested
by significantly reduced incidence, joint synovial injury,
and inflammatory factors secretion [7]. In addition, oral
treatment of SM905 skewed the T cell subset frompathogenic
Th17 to protectiveTh2 subset in CIAmodel. SM905 treatment
increased IL-4 production from T cells and suppressed the
ROR𝛾t mRNA expression and IL-17 production from T cells.
K/BxN mice spontaneously develop an autoimmune
arthritis disease with many clinical, histopathological, and
immunological features of the human rheumatoid arthri-
tis. Breakdown of T and B cells tolerance leads to the
production of high-titer autoantibodies against glucose-6-
phosphate isomerase (GPI), which can directly induce joint
pathology. Given the well-studied disease mechanisms and
clearly defined roles of various immune cells, K/BxN mice
have been an informative model to investigate therapeutic
agents targeting antibody-mediated autoimmune diseases. A
recent study by Hou et al. demonstrated that artemisinin
analog artesunate remarkably ameliorated the arthritis in
K/BxN mouse [28]. Artesunate treatment prevented the
arthritis development in young K/BxN mice by inhibiting
germinal center formation and production of autoantibodies.
In adult K/BxN mice with established arthritis, artesunate
treatment rapidly diminished germinal center B cells in a few
days. However, artesunate did not affect the follicular helper
T cells (Tfh). In contrast to the spontaneous K/BxN model,
artesunate treatment exerted minor influence on K/BxN
serum transfer induced arthritis, suggesting that artesunate
has minor effects on inflammatory responses downstream of
antibody production.Thus, authors demonstrated that highly
proliferativeGCB cells were themost sensitive cellular targets
to artesunate treatment. Besides, in rat model of Freund’s
complete adjuvant-induced arthritis, artesunate was found
to produce dose-dependent reduction in joint inflammation
and improvement in functional parameters, including stair
climbing ability, motility, and suppression of mechanical
allodynia [29, 30].
In addition to the animal model, artemisinin derivatives
also showed promising effects on human rheumatoid arthri-
tis. In vitro, artesunate could significantly inhibit IL-1𝛽, IL-6,
and IL-8 production from synovial cells of RA patients, when
stimulated with TNF-𝛼. Further studies demonstrated that
artesunate inhibited Akt phosphorylation and I𝜅B degrada-
tion by blocking PI3K/Akt signaling pathway downstream of
TNF-𝛼 [30, 31].
3.3. Artemisinin Derivatives Treat Systemic Lupus Erythe-
matosus. Systemic lupus erythematosus (SLE) is a chronic
autoimmune disease characterized by abnormal accumu-
lation of autoreactive T lymphocytes and production of
autoantibody against self-antigen, which result in the devel-
opment of immune complex-mediated glomerulonephritis
and renal failure. Female MRL/lpr mice and NZBW/F1 mice
were two well-established murine models for lupus study
and represent human lupus disease closely [32]. Hou et al.
showed SM934 is able to significantly prolong the lifespan
and limit the glomerulonephritis in the MRL/lpr mice by
inhibiting bothTh1 andTh17 responses [10]. The therapeutic
properties of SM934 were characterized by suppressing the
serum level of pathogenic cytokines interferon-𝛾 (IFN-𝛾) and
interleukin-10 (IL-10), reducing the secretion and deposition
of pathogenic anti-dsDNA IgG autoantibodies in serum and
kidneys, and ameliorating the renal injury. SM934 treatment
also rectified the abnormal lymphocyte development includ-
ing reduced double negative T cells (DN T) and elevated
conventional single positive T cells and B cells in the spleen.
In addition, SM934 treatment reduced the proportion of
CD4+CD44+CD62L− Teff in spleens. Further investigations
revealed that SM934 treatment significantly suppressed the
excessive activation of STAT1, STAT3, and STAT5 in lupus.
In NZB/W F1 mice, the fas gene is intact, which makes
the pathogenesis of NZB/W F1 mice largely different from
that of MRL/lpr mice [33]. However, SM934 also exerts
comprehensive therapeutic effects on NZB/W F1 mice both
in short-term and long-term treatment [9]. Similarly to
MRL/lpr mice, SM934 treatment could significantly increase
Treg percentage and suppress the Th1 and Th17 responses
in NZB/W F1 mice. Clinical improvement was accompanied
with decreased Th1-related anti-dsDNA IgG2a and IgG3 Abs
and serum IL-17 and increasedTh2-related anti-dsDNA IgG1
Ab, serum IL-10, and IL-4. Furthermore, the therapeutic
effects of SM934 on NZB/W F1 mice were tightly linked to
enhancing IL-10 production from macrophages, which was
absent in MRL/lpr mice.
In another mouse model of lupus BXSB, dihydroartemi-
sinin was found to significantly improve lupus nephritis,
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reduce serum TNF𝛼 level, and suppress TNF𝛼 production
from peritoneal macrophages [34].
3.4. Artemisinin Derivatives TreatMultiple Sclerosis. Multiple
sclerosis (MS) is a class of autoimmune disease occurring in
the central nervous system, which was mediated by both of
Th17- and Th1-type T cells. The main symptom of patients
with MS was progressive paralysis. Experimental allergic
encephalomyelitis (EAE) is a well-established murine model
to study the pathogenesis of MS and for drug screening.
Several artemisinin derivatives were reported to treat EAE
including SM933, SM934, and dihydroartemisinin (DHA)
with different mechanisms [8, 12, 35]. In 2007, SM933 was
reported to possess unique anti-inflammatory properties
through regulation of signaling pathways, leading to ame-
lioration of EAE [35]. The anti-inflammatory properties
of SM933 were characterized by a regulatory mechanism
involving the NF𝜅B and the Rig-G/JAB1 signaling pathways.
Regulation of the Rig-G/JAB1 pathway by SM933 led to
altered cell cycle activity of encephalitogenic T cells as a result
of its selective effect on activated, but not resting, T cells.
In contrast to SM933, both SM934 andDHAwere demon-
strated to treat EAE majorly through regulating the balance
between effector T cells and regulatory T cells. Zhao et al.
found that administration of DHA significantly decreased
effector CD4 T cells but increased Tregs in EAE mice [8].
Their study argued that DHA reciprocally regulates effector
T cell and regulatory T cell generation through modulating
mTOR pathway. On top of DHA work, through both BrdU
incorporation strategy and in vitroTreg differentiation assays,
Zuo group in SIMM further revealed that SM934 treatment
could directly promote the expansion of Treg cells in vivo and
in vitro [12].
3.5. Artemisinin Derivatives Treat Allergic Diseases. Allergy is
an acquired hypersensitivity reaction of the immune system
mediated by cross-linking of allergen-specific IgE with high-
affinity IgE receptors, leading to immediate mast cell degran-
ulation. Allergic disorders have substantially different patho-
genesis with autoimmune diseases. However, artemisinin
derivatives were also reported to be therapeutic against the
allergic diseases [36–38]. Several studies by Wong group
demonstrated that artesunate ameliorates experimental aller-
gic airway inflammation probably via negative regulation
of PI3K/Akt pathway and blocking IgE-induced mast cell
degranulation. A recent study also reported that artesunate
could suppress the proliferation of airway smooth muscle,
which further strengthened the reasonability for artesunate
to treat allergic airway disorders.
4. Structure-Activity Relationship
It is broadly accepted that artemisinin exerts antimalarial
effects through the following molecular mechanisms: Heme
or free iron will break the peroxide bridge, which results in
the degradation of the molecular structure of artemisinin
to form the nucleophilic radical metabolites. Consequently,
the free radicals, acting as an alkylating agent, will attack
macromolecular bearing electrophilic groups or centers,
which eventually leads to cell damage [17]. One elegant study
showed that artemisinin inhibits endoplasmic reticulum
Ca2+-ATPase (SERCA), resulting in calcium to accumulate
in the cytoplasm [39].The high concentration of cytoplasmic
calcium activates a secondary influx of calcium into the cell,
which induces the apoptosis. Thapsigargin (TG), a specific
inhibitor of SERCA, could induce intracellular calcium accu-
mulation and leads to cell apoptosis. TG is structurally similar
to artemisinin, which allows it to antagonize the inhibition of
artemisinin activities on SERCA in vitro. There are further
evidences showing that TG and artemisinin have the same
binding site [17]. Sequence alignments of the thapsigargin-
binding pocket of mammalian SERCAs and from different
Plasmodium spp. show several amino acids that differ among
SERCAs. Further structural biology study demonstrated that
a single amino acid (Leu263) in transmembrane segment
3 of SERCAs can determine susceptibility to artemisinin.
Introduction of a residue in Plasmodium vivax SERCA
(PvSERCA) increased sensitivity to artemisinins by threefold,
whereas introduction of a residue in Plasmodium berghei
SERCA (PbSERCA) decreased sensitivity by threefold [39,
40].
Although peroxide bridge plays a necessary role in the
biological activity of artemisinin, finding in stereochemistry
indicates that the binding site of artemisinin and SERCA
does not include the peroxide bridge [41]. We hypothesize
that peroxide bridge might act as a “catalyst” for artemisinin
to inhibit SERCA. According to stereochemistry and tran-
sitional state theory, when the peroxide bridge is intact, the
spatial configuration of artemisinin is relatively rigid, and
the sesquiterpene lactone structure might not be able to
flexibly rotate and fold. In this case, artemisinin has relatively
lower affinity to SERCA. However, once the peroxide bridge
has been reduced by divalent iron ion and broken, the
sesquiterpene lactone part will be released and will be flexible
and will bind to SERCA with high affinity. As a result, the
inhibitory effect of artemisinin against SERCA is enhanced.
Studies have found that, in parasites-infected red blood
cells and activated lymphocytes, the divalent iron ion level
is significantly higher than the resting state/cells. In this
case, the opportunity for peroxide bridge to be broken is
largely increased, which consequently makes the activated
cells, rather than the resting cells, much more vulnerable
to artemisinin. In conclusion, the peroxide bridge is a
unique structure and is essential for the biological activity
of artemisinin. Furthermore, since mammalian SERCAs
are not susceptible to inhibition by artemisinins [39], the
biochemical mechanism and molecular target of artemisinin
to exert immunosuppressive function still need to be further
studied.
5. Summary and Future Outlook
Artemisinin and its derivatives are potent antimalarial agents
with high efficacy and low toxicity. Besides the outstanding
antimalarial activity, artemisinin and its derivatives also
possess immunosuppressive activities and are experimentally
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Figure 2: Schematic of artemisinin derivatives affecting immune and inflammation.
used to treat autoimmune diseases, such as SLE, RA, and
CIA. In this paper, we summarized the recent progress of
artemisinin derivatives in treating autoimmune and allergic
disorders. We conclude that artemisinin derivatives perform
immunosuppressive functions primarily through inhibiting
pathogenic T cell activation, suppressing B cells activa-
tion and antibody production, and expanding regulatory T
cells (impact of artemisinins and derivatives on different
immune cells is shown in Figure 2). We deem that, as anti-
inflammatory agents, artemisinin derivatives possess more
advantages to act onmultiple checkpoints within the immune
signaling cascade, with selectivity for activated pathogenic
T cells, to create a synergistic treatment effect on disease
activity. Thus, these new artemisinin derivatives may be a
kind of promising candidates to treat inflammation and
autoimmune disorders.
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